Previous literature show that a small to undetectable magnitude of type-I IFN can have high potency of biological effects, such as the conditions that are involved in osteoclast inhibition and 'IFN signature' of ISG expression in systemic lupus erythematosus (SLE) (Binder et al., 2017; Ivashkiv and Donlin, 2014; Takayanagi et al., 2002; Inoue et al., 2018). This evidence concerns the gene IFNA1 and systemic lupus erythematosus.